Thymosin Alpha-1Also known as: Tα1, Thymalfasin

Mechanism of Action

Thymosin Alpha-1 modulates the immune system primarily through the activation and regulation of T lymphocytes and other immune cells. It promotes T-cell differentiation and maturation, enhances dendritic cell function, and stimulates the production of cytokines and interferons, thereby improving immune surveillance, antiviral responses, and inflammatory control. This peptide helps restore immune homeostasis and enhances the body's ability to fight infections and regulate inflammatory processes.

Reported Research Benefits

Research into immune system enhancement, antiviral and antimicrobial defense, modulation of inflammatory processes, support of cell and tissue repair, investigation of chronic infections, oncology-related immune response, oxidative stress studies, and auto-immune disorder mechanisms.

Dosing Protocol & Reconstitution

Typical laboratory research dosing involves reconstitution of lyophilized powder in bacteriostatic water followed by subcutaneous injections, often dosed in micrograms per kilogram in animal models or appropriate volumes in cell culture assays. Clinical therapeutic regimens (not for research use) may range from 0.8 mg to 1.6 mg twice weekly in human studies, but research doses should be strictly adjusted to experimental design.

Research Notes

Demonstrates potential to improve immune response efficacy, reduce inflammation, and promote cellular regeneration. Half-life in circulation is approximately 2-3 hours when administered subcutaneously. Synergistic effects observed when combined with other immunomodulatory agents. Safety profile in research is generally favorable with low toxicity.

Research Summary

Thymosin Alpha-1 (Tα1, Zadaxin) is a 28-amino-acid thymic peptide that serves as a master immune modulator, enhancing T-cell maturation, NK cell activity, dendritic cell function, and antigen-specific immunity. It is approved in 35+ countries for chronic hepatitis B/C, immune deficiency, and as an adjuvant for cancer vaccines. During COVID-19, it was shown to reduce mortality in severe cases.

Side Effects & Safety

Excellent safety profile across extensive clinical use. Mild injection site reactions are the primary complaint. No serious immunotoxicity. Potential to exacerbate autoimmune conditions with prolonged use due to immune upregulation. Well-tolerated in immunocompromised populations.

Stability & Storage

Refer to research notes

Molecular Data

Sequence: Ac-Ser-Asp-Ala-Val-Asp-Thr-Ser-Ser-Ala-Glu-Ile-Thr-Thr-Leu-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Lys-Glu-NH2
Molecular Formula: C129H203N39O41S1
Molecular Weight: 3108.6 g/mol
CAS Number: 170851-70-4

Primary literature: https://pubmed.ncbi.nlm.nih.gov/?term=Thymosin+alpha-1+immune+modulation+infection